🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. Amlitelimab, Placebo, -, TACROLIMUS , PIMECROLIMUS , Amlitelimab

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  2. Amlitelimab, Placebo, Amlitelimab, PIMECROLIMUS , -, TACROLIMUS

    Sanofi-aventis Healthcare Pty Ltd

    atopic dermatitis

    phase 3 small molecule active

    1 trial

  3. Amlodipine

    United Therapeutics Europe Ltd

    Depression

    phase 3 small molecule active

    1 trial

  4. Amlodipine

    The First People's Hospital of Lianyungang

    Sleep Apnea Syndrome

    phase 3 small molecule active

    1 trial

  5. Amoxycillin

    United Therapeutics Europe Ltd

    Non-Severe Pneumonia With Wheeze

    phase 3 small molecule completed

    1 trial

  6. Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  7. Amvuttra 25 mg solution for injection in pre-filled syringe, Onpattro 2 mg/mL concentrate for solution for infusion.

    Alnylam Netherlands B.V.

    Hereditary Transthyretin Amyloidosis

    phase 3 small molecule active

    1 trial

  8. Amyvid 1900 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Trontinemab, Placebo Trontinemab, Amyvid 800 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, Amyvid 1900 MBq/mL solution for injection, [18F]MK-6240

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)

    phase 3 small molecule active

    1 trial

  9. An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome

    CORCEPT THERAPEUTICS INC

    Endogenous Cushing Syndrome

    phase 3 other active

    1 trial

  10. An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria

    Lacuna Pharma Pty Ltd

    Primary Hyperoxaluria

    phase 3 other active

    1 trial

  11. An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)

    Boehringer Ingelheim

    Schizophrenia

    phase 3 other active

    1 trial

  12. Anagrelide Hydrochloride

    Takeda

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial

  13. Anakinra 100mg and Placebo Depo-Medrone

    United Therapeutics Europe Ltd

    Gout

    phase 3 small molecule completed

    1 trial

  14. Anastrozole

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 small molecule active

    2 trials

  15. Angoron 150 mg/3 ml amp ενέσιμο διάλυμα, FLECARDIA Διάλυμα για ένεση/έχχυση

    Lacuna Pharma Pty Ltd

    Cardioversion of paroxysmal atrial fibrillation in the Emergency Department in patients with coronary artery disease without residual ischemia and an left ventricular ejection fraction > 35%

    phase 3 small molecule active

    1 trial

  16. Anifrolumab

    AstraZeneca

    Active Systemic Lupus Erythematosus

    phase 3 mab completed

    3 trials

  17. Anifrolumab

    AstraZeneca

    Cutaneous Lupus Erythematosus

    phase 3 other active

    1 trial

  18. Anifrolumab

    AstraZeneca AB

    Moderate-to-severe Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  19. Anifrolumab

    AstraZeneca

    Systemic Lupus Erythematosus

    phase 3 mab active

    1 trial

  20. Anifrolumab, Matching placebo solution for injection in aPFS; 0.8 mL fill volume

    AstraZeneca AB

    Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  21. Anodal tDCS

    United Therapeutics Europe Ltd

    Stroke

    phase 3 other active

    1 trial

  22. Anti C5 Complement mAb Placebo, Ultomiris 300 mg/30 mL concentrate for solution for infusion

    Alexion Europe SAS

    Hematopoietic stem cell transplant-associated thrombotic microangiopathy

    phase 3 small molecule active

    1 trial

  23. Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method

    Baxalta Innovations GmbH

    Hemophilia A

    phase 3 mab completed

    1 trial

  24. Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)

    Takeda

    Hemophilia A

    phase 3 mab terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources